Samyang Biopharm is a multinational biopharmaceutical company, part of South Korean conglomerate, Samyang Group. Samyang Biopharm operates across medical surgical care, medical aesthetics, anti-cancer generics, and nucleic acid (RNA) therapeutics. The company is advancing its proprietary drug delivery technology platform, SENS™ that enables next generation gene therapies, including mRNA-based therapeutics and vaccines.

• About SENS™, Selectivity Enabling NanoShell:
  • SENS™ is a novel drug delivery platform for organ and cell-selective delivery of nucleic acid (RNA) therapeutics.
  • SENS™ enables targeted delivery of mRNA to specific tissues (e.g., spleen, lung, muscle, CNS, liver) while offering superior safety profiles that support repeat dosing. Samyang is actively seeking strategic partnerships with drug developers aiming to bring RNA therapies into the clinic.